Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT04963283	TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Fase Fase 2	Date Added 2021-07-15	Ubicación Colorado, United States	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Cabozantinib, Nivolumab	Etiquetas MSS/ MMRp
NCT ID NCT04948034	TitleLa combinación de fruquintinib, tislelizumab y radioterapia ablativa estereotáctica en el cáncer colorrectal metastásico (RIFLE)	Fase Fase 2	Date Added 2021-07-01	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Fruquintinib, Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04940546	TitleNeoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in pMMR/MSS CRLM Patients	Fase Phase 1, Phase 2	Date Added 2021-06-25	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Bevacizumab, capecitabine, oxaliplatin, Sintilimab	Etiquetas MSS/ MMRp
NCT ID NCT04895709	TitleEstudio de BMS-986340 como monoterapia y en combinación con nivolumab en participantes con tumores sólidos avanzados.	Fase Phase 1, Phase 2	Date Added 2021-05-20	Ubicación California, United States Iowa, United States New Jersey, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Australia Canadá Alemania Israel Italia Japón España	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas BMS-936558-01, BMS-986340	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04895722	TitleEvaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)	Fase Fase 2	Date Added 2021-05-20	Ubicación Florida, United States Georgia, United States Illinois, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Bélgica Canadá Colombia Costa Rica Dinamarca Estonia Francia Alemania Greece Guatemala Hungary Italia Corea, República de Lithuania Países Bajos Polonia Romania Russian Federation España Turkey Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Favezelimab/Pembrolizumab, Pembrolizumab/Quavonlimab, pembrolizumab/vibostolimab coformulation, Keytruda	Etiquetas MSI-H/ MMRd
NCT ID NCT04874259	TitleLT para metástasis hepáticas colorrectales no resecables	Fase No aplicable	Date Added 2021-05-05	Ubicación Corea, República de	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04866862	TitleFruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer	Fase Fase 2	Date Added 2021-04-30	Ubicación China	Prior IO Allowed No	CRC-directed Sí	Status Reclutamiento	Drogas Combination of Fruquintinib and Camrelizumab	Etiquetas MSS/ MMRp
NCT ID NCT04853017	TitleELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)	Fase Fase 1	Date Added 2021-04-21	Ubicación California, United States Colorado, United States Iowa, United States Massachusetts, United States Missouri, United States New York, United States Tennessee, United States Texas, United States	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04793958	TitleEstudio de fase 3 de MRTX849 con cetuximab frente a quimioterapia en pacientes con cáncer colorrectal avanzado con mutación KRAS G12C (KRYSTAL-10)	Fase Fase 3	Date Added 2021-03-11	Ubicación Alabama, United States Arizona, United States Arkansas, United States California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Iowa, United States Louisiana, United States Maryland, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States West Virginia, United States Wisconsin, United States Argentina Australia Austria Bélgica Brasil Canadá China Colombia Czechia Dinamarca Finland Francia Alemania Greece Hong Kong Ireland Italia Corea, República de Malaysia Mexico Países Bajos Polonia Portugal Puerto Rico Romania Singapur España Taiwán Tailandia Ukraine Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, FOLFIRI Regimen, mFOLFOX6 Regimen, MRTX849	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04776148	TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)	Fase Fase 3	Date Added 2021-03-01	Ubicación California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canadá China Dinamarca Alemania Israel Japón Corea, República de Russian Federation España Taiwán Turkey Reino Unido	Prior IO Allowed No	CRC-directed Sí	Status Activo, no recluta	Drogas Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)	Etiquetas MSS/ MMRp

Showing 131 to 140 of 299 entries